Summary
Thermo Fisher Scientific Inc. (TMO) has announced a definitive agreement to acquire PPD, Inc. (PPD) for $47.50 per share in cash. This acquisition, valued at approximately $17.4 billion (including PPD's net debt), is expected to significantly enhance Thermo Fisher's capabilities in serving pharmaceutical and biotechnology customers. The transaction is funded through a combination of cash and a $9.5 billion bridge loan facility. Regulatory approvals, including HSR Act clearance, and other customary closing conditions must be met before the merger can be completed. PPD's stockholders have already approved the merger through written consent, representing approximately 60% of the outstanding shares. This strategic move positions Thermo Fisher to capitalize on the growing demand for clinical research services. The acquisition is expected to be completed in the second half of 2021. Investors should note that the agreement includes standard representations, warranties, and covenants, and PPD has agreed to customary restrictions on soliciting alternative acquisition proposals. The full details of the Merger Agreement, including omitted schedules, will be available upon request from the SEC.
Key Highlights
- 1Thermo Fisher Scientific Inc. to acquire PPD, Inc. for $47.50 per share in cash.
- 2The total transaction value is approximately $17.4 billion, including PPD's net debt.
- 3The acquisition is expected to significantly bolster Thermo Fisher's offerings to pharma and biotech clients.
- 4Funding for the merger will comprise existing cash and a $9.5 billion bridge loan facility.
- 5PPD's stockholders have already approved the merger via written consent.
- 6The transaction is subject to customary closing conditions, including regulatory approvals like HSR Act clearance.
- 7The merger is anticipated to close in the second half of 2021.